Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Invested Capital (2016 - 2025)

Adma Biologics filings provide 15 years of Invested Capital readings, the most recent being $480.1 million for Q4 2025.

  • On a quarterly basis, Invested Capital rose 37.57% to $480.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $480.1 million, a 37.57% increase, with the full-year FY2025 number at $480.1 million, up 37.57% from a year prior.
  • Invested Capital hit $480.1 million in Q4 2025 for Adma Biologics, up from $433.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $480.1 million in Q4 2025 to a low of $100.4 million in Q3 2022.
  • Median Invested Capital over the past 5 years was $149.1 million (2023), compared with a mean of $207.5 million.
  • Biggest five-year swings in Invested Capital: dropped 11.03% in 2023 and later surged 158.14% in 2024.
  • Adma Biologics' Invested Capital stood at $141.2 million in 2021, then increased by 7.65% to $152.0 million in 2022, then fell by 11.03% to $135.2 million in 2023, then surged by 158.14% to $349.0 million in 2024, then skyrocketed by 37.57% to $480.1 million in 2025.
  • The last three reported values for Invested Capital were $480.1 million (Q4 2025), $433.5 million (Q3 2025), and $398.3 million (Q2 2025) per Business Quant data.